HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel).

AbstractOBJECTIVE:
Our goal was to determine the effects of a repeated course of the gonadotropin-releasing hormone agonist nafarelin on symptoms and signs of endometriosis and lumbar and distal radius bone mineral density.
STUDY DESIGN:
Forty-five women previously treated for 6 months with nafarelin, who had recurrent symptoms and signs of endometriosis, received 400 mcg/day of nafarelin intranasally for 3 months. Efficacy was evaluated by changes in severity of symptoms and signs. Lumbar bone mineral density was measured by dual-energy x-ray absorptiometry and distal radius bone mineral density by single-photon absorptiometry. Bone mineral density was also measured in 10 control volunteers.
RESULTS:
Repeated 3-month treatment significantly alleviated recurrent symptoms and signs of endometriosis. Lumbar bone mineral density decreased significantly by a mean of 2% at the end of treatment; this loss was restored within 3 to 6 months after treatment completion. No bone mineral density decline occurred in the radius. Bone mineral density changes in the control group were statistically insignificant.
CONCLUSIONS:
A repeated 3-month course of nafarelin treatment significantly relieved recurrent endometriotic symptoms and signs without sustained loss of bone mineral density.
AuthorsG D Adamson, W L Heinrichs, M R Henzl, A A Yuzpe, C Bergquist, J J Jacobson, S Eriksson, L Kwei, S M Gilbert
JournalAmerican journal of obstetrics and gynecology (Am J Obstet Gynecol) Vol. 177 Issue 6 Pg. 1413-8 (Dec 1997) ISSN: 0002-9378 [Print] UNITED STATES
PMID9423744 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hormones
  • Nafarelin
  • Estradiol
Topics
  • Adult
  • Bone Density
  • Endometriosis (drug therapy, metabolism)
  • Estradiol (blood)
  • Female
  • Hormones (adverse effects, therapeutic use)
  • Humans
  • Menstrual Cycle (blood)
  • Middle Aged
  • Nafarelin (adverse effects, therapeutic use)
  • Recurrence
  • Retreatment
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: